Home » Stocks » BGNE

BeiGene Ltd. (BGNE)

Stock Price: $222.88 USD 1.57 (0.71%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $222.00 -0.88 (-0.40%) Dec 4, 5:42 PM

BGNE Stock Price Chart

Key Info

Market Cap 20.90B
Revenue (ttm) 265.67M
Net Income (ttm) -1.51B
Shares Out 1.15B
EPS (ttm) -19.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $222.88
Previous Close $221.31
Change ($) 1.57
Change (%) 0.71%
Day's Open 222.57
Day's Range 220.64 - 228.64
Day's Volume 639,450
52-Week Range 121.84 - 316.61

BGNE Stock News

Business Wire - 1 week ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing in...

Seeking Alpha - 1 week ago

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (S...

Business Wire - 2 weeks ago

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.

GuruFocus - 2 weeks ago

Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and ...

Other stocks mentioned: HCM
Business Wire - 2 weeks ago

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim...

Seeking Alpha - 2 weeks ago

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...

Other stocks mentioned: BNTX, CALT, IMAB, MRK, PFE, TMO
Business Wire - 3 weeks ago

HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics Licens...

Business Wire - 4 weeks ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene reports recent business highlights, anticipated upcoming milestones and financial results for the third quarter and first n...

Business Wire - 1 month ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA® (zanubrutinib) and tislelizumab to be presented at the 62nd ASH Annual Meeting.

Business Wire - 1 month ago

SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla's investigat...

Zacks Investment Research - 2 months ago

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 2 months ago

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Other stocks mentioned: EBS, HZNP, RGEN
Zacks Investment Research - 2 months ago

As of late, it has definitely been a great time to be an investor in BeiGene.

The Motley Fool - 2 months ago

Want to invest in an industry that consistently outperforms the S&P 500? Here are three stocks to consider.

Other stocks mentioned: ALXN, BNTX
Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer and Phase 2 data of pamiparib in ovarian c...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thurs, Sept 17...

Business Wire - 2 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Health Canada accepted BeiGene's New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s macroglobulinemia (WM) and grant...

Business Wire - 3 months ago

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion in Shanghai-Hong Kong Stock Connect and inclusion in Hang Seng Composite Index (HSCI).

Seeking Alpha - 3 months ago

BeiGene COVID-19 Deal And Other News: The Good, Bad And Ugly Of Biopharma

Business Wire - 3 months ago

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Singlomics enter an exclusive license agreement for Singlomics’ investigational anti-COVID-19 antibodies, includ...

Business Wire - 3 months ago

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene appoints Corsee Sanders, Ph.D.

Business Wire - 3 months ago

GUANGZHOU & BEIJING & CAMBRIDGE, Mass--(BUSINESS WIRE)---- $BGNE--Bio-Thera Solutions and BeiGene announce license, distribution, and supply agreement for Avastin® (bevacizumab) biosimilar BAT...

Zacks Investment Research - 3 months ago

BeiGene, Ltd. (BGNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 4 months ago

BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center fo...

Forbes - 4 months ago

More than 100% stock gain without posting an operating profit - that’s what Autodesk, Alnylam Pharma, BeiGene, Chegg, and Coupa Software have done over the past three years! This counter-intui...

Other stocks mentioned: ADSK, COUP
GlobeNewsWire - 4 months ago

BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

The Motley Fool - 4 months ago

Investors cheered another big investment in the Chinese biotech.

Zacks Investment Research - 4 months ago

BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Benzinga - 4 months ago

BeiGene (NASDAQ: BGNE) shares are trading higher on Monday after Amgen announced a $421 million investment in the company.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 5 months ago

BEIJING, China and CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and BEIJING, China, July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 5 months ago

BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 5 months ago

BEIJING, China and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercia...

GlobeNewsWire - 6 months ago

First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma First approvals for BRUKINSA in China and its fir...

GlobeNewsWire - 6 months ago

- Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VG...

GlobeNewsWire - 6 months ago

– Collaboration to explore multiple solid tumor cancer indications –

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on ...

GlobeNewsWire - 7 months ago

BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commerci...

GlobeNewsWire - 7 months ago

BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commerc...

GlobeNewsWire - 7 months ago

Second approval of tislelizumab in China, first in solid tumor Second approval of tislelizumab in China, first in solid tumor

Bloomberg Markets and Finance - 7 months ago

BeiGene CEO on Coronavirus Impact, China Biopharma, Product Pipeline

John Oyler, chairman and chief executive officer at BeiGene Ltd., discusses how coronavirus has impacted the business and his outlook for China’s Biopharma sector. He speaks on “Bloomberg Mark...

GlobeNewsWire - 8 months ago

- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company

GlobeNewsWire - 9 months ago

-- Phase 1 Study Initiated in Australia with IND Cleared to Expand Study to the U.S.-- -- Industry-Leading Scientific Advisory Board Formed to Support Advancement of BGB-3245 --

The Motley Fool - 10 months ago

BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.

Other stocks mentioned: VRTX

About BGNE

BeiGene,, a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumo... [Read more...]

Industry
Biotechnology
IPO Date
Feb 3, 2016
CEO
John Oyler
Employees
4,600
Stock Exchange
NASDAQ
Ticker Symbol
BGNE
Full Company Profile

Financial Performance

In 2019, BeiGene's revenue was $428.21 million, an increase of 116.03% compared to the previous year's $198.22 million. Losses were -$948.63 million, 40.8% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for BeiGene is 293.38, which is an increase of 31.63% from the latest price.

Price Target
$293.38
(31.63% upside)